Last edition
News about "Indian Pharma Faces Diverging Fortunes Amid Growth"
Indian Pharma Faces Diverging Fortunes Amid Growth in CDMO and API Segments
Operational gains were seen in EBITDA margin expansion, aided by improved product mix and execution in regulated markets. ROCE, however, remained muted due to under-utilised greenfield facilities and acquisition-led debt. Companies are rationalising R&D investments to monetise existing ANDA filings rather than prioritising fresh approvals.
Indian Pharma Faces Diverging Fortunes Amid Growth | 16/07/2025 | By Darshana | 669
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy